Lyvedon-MR Tablet contains Trimetazidine 35 mg, an anti-ischemic metabolic agent primarily used in the management of angina pectoris. Trimetazidine acts by improving myocardial glucose utilization through inhibition of fatty acid metabolism, thereby enhancing cellular energy metabolism and reducing ischemic damage to cardiac cells. This mechanism helps to maintain cellular homeostasis during ischemic episodes without affecting hemodynamic parameters such as heart rate or blood pressure. Lyvedon-MR is indicated as an adjunct therapy in the treatment of stable angina pectoris to reduce the frequency of anginal attacks and improve exercise tolerance. It is also beneficial in patients who are unable to tolerate conventional antianginal drugs or in combination with other therapies for optimal symptom control. The extended-release formulation allows for once-daily dosing, improving patient compliance. Lyvedon-MR should be used under medical supervision, with caution advised in patients with severe renal impairment. Common side effects may include gastrointestinal disturbances, headache, and dizziness, although it is generally well tolerated. Contraindications include hypersensitivity to Trimetazidine or any excipients. Patients should inform their healthcare provider of any other medications or underlying conditions before initiating therapy with Lyvedon-MR.